ShedRx vs MEDVidi
Two GLP-1 desks, one scoreboard. We put ShedRx and MEDVidi head-to-head on the published Brief Score — the same six factors, scored the same way.
The verdict
ShedRx takes this head-to-head.
ShedRx scores 87 to 51 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.
That doesn't make MEDVidi a bad call — it's best for people who want a licensed provider to prescribe brand glp-1 they fill with insurance. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| ShedRx | MEDVidi | |
|---|---|---|
| Brief Score | 87/100 (B+) | 51/100 (C) |
| Semaglutide | $199/mo | Not disclosed |
| Tirzepatide | $299/mo | Not disclosed |
| Coverage | Not disclosed | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Fallingprice falling | Newnew to the tracker, no prior reading |
ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.
MEDVidi: New to the tracker on 1 August 2026. This program publishes no monthly medication price, so there is no line for us to track until it does.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.